Table 1.
Number of cells (%) expressing CSF-1R
| ctrl | Without FBS | csf-1r siRNA | Non-coding siRNA | CSF-1 25 ng/ml | CSF-1 50 ng/ml | CSF-1 100 ng/ml | |
|---|---|---|---|---|---|---|---|
| CMT-U27 |
72.10 |
73.4 |
15.65*** |
75.80 |
99.85*** |
99.80*** |
99.65*** |
| CMT-U309 |
66.80 |
70.0 |
3.00*** |
64.40 |
99.75* |
99.85* |
99.65* |
| P114 |
88.70 |
73.7 |
38,45*** |
90.85 |
99.80* |
99.80* |
99.90* |
| CMT-W1 |
80.45 |
73.6 |
23.45*** |
82.30 |
99.55** |
99.55** |
99.75** |
| CMT-W2 | 58.70 | 52.3 | 23.15*** | 64.80 | 99.35*** | 99.10*** | 99.55*** |
The number of CSF-1R expressing cells obtained with FACS Aria II (Becton Dickinson). The number of cells which express CSF-1R is significantly decreased after the csf-1r specific siRNA treatment and significantly increased after treatment with CSF-1 at the dose of 25, 50 and 100 ng/ml (no significant differences between these doses have been observed). Treatment of cells with non-coding siRNA did not cause any effect. The experiment has been conducted in three replicates. P<0.05 was regarded as significant and marked as *, whereas p<0.01 and p<0.001 was regarded as highly significant and marked as * and ***, respectively. One-way ANOVA followed by Tukey HSD post-hoc test were applied.